Sutro Biopharma, Inc. (S09.F)

6.50 -0.15 (-2.26%) As of 09:15AM CET. Market open.

Sutro Biopharma, Inc.

111 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 881 6500
https://www.sutrobio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 259

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. William J. Newell J.D.	CEO & Director	1.06M	N/A	1958
Mr. Edward C. Albini	CFO & Sec.	596.4k	N/A	1958
Dr. Trevor J. Hallam	Pres of Research & Chief Scientific Officer	882.83k	467.17k	1959
Ms. Jane Chung R.Ph.	Chief Commercial Officer	832.52k	N/A	1971
Dr. James R. Swartz Ph.D., Sc.D.	Founder	N/A	N/A	N/A
Dr. Shabbir T. Anik	Chief Technical Operations Officer	N/A	N/A	1953
Ms. Annie J. Chang M.B.A.	VP of Investor Relations	N/A	N/A	N/A
Mr. David Pauling J.D., M.A.	Gen. Counsel	N/A	N/A	N/A
Ms. Linda A. Fitzpatrick	Chief People & Communications Officer	N/A	N/A	1957
Dr. Nicki Vasquez Ph.D.	Chief Portfolio Strategy & Alliance Officer	N/A	N/A	1963

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Corporate Governance

Sutro Biopharma, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.